Introduction Parkinsons disease (PD) is the second most common neurodegenerative disease worldwide with 6.1 million patients globally in 2016 (GBD 2016 Parkinsons Disease Collaborators, 2018), and up to 12.9 million people estimated to be affected by 2040 (Dorsey and Bloem, 2018)
Placebo-controlled studies have shown that this delayed gastric motility is associated with reduced overall food intake and weight loss over weeks to months of treatment
At Better Med Spa, AOD9604 is framed as a potential nudge for fat metabolism that only makes sense when layered onto disciplined nutrition, movement, and sometimes GLP1 or other medical therapies
After Botox is injected, the proteins start to diffuse in the treated area
Following dosing, the ARA 290 group increased their walk distance by a mean of 3.5% of baseline ( p = 0.09), whereas the placebo group increased walk distance by 1.1 % of baseline ( p = ns [not significant])
Scientists are exploring its potential benefits in healing and recovery